A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A
Public ClinicalTrials.gov record NCT03528551. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia A
Study identification
- NCT ID
- NCT03528551
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Interventions
- Turoctocog alfa pegol Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2018
- Primary completion
- Dec 2, 2020
- Completion
- Dec 2, 2020
- Last update posted
- Dec 21, 2022
2018 – 2020
United States locations
- U.S. sites
- 18
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Phoenix | Arizona | 85016-7710 | — |
| Novo Nordisk Investigational Site | Long Beach | California | 90806 | — |
| Novo Nordisk Investigational Site | Iowa City | Iowa | 52242 | — |
| Novo Nordisk Investigational Site | New Orleans | Louisiana | 70118-5720 | — |
| Novo Nordisk Investigational Site | Baltimore | Maryland | 21205 | — |
| Novo Nordisk Investigational Site | Detroit | Michigan | 48201 | — |
| Novo Nordisk Investigational Site | East Lansing | Michigan | 48824 | — |
| Novo Nordisk Investigational Site | Minneapolis | Minnesota | 55404 | — |
| Novo Nordisk Investigational Site | New Hyde Park | New York | 11040 | — |
| Novo Nordisk Investigational Site | Charlotte | North Carolina | 28204 | — |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45229 | — |
| Novo Nordisk Investigational Site | Dayton | Ohio | 45404 | — |
| Novo Nordisk Investigational Site | Portland | Oregon | 97239 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Novo Nordisk Investigational Site | Charleston | South Carolina | 29425 | — |
| Novo Nordisk Investigational Site | Nashville | Tennessee | 37232-9830 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
| Novo Nordisk Investigational Site | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03528551, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03528551 live on ClinicalTrials.gov.